{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:16:09Z","timestamp":1795025769927,"version":"4.10.2"},"reference-count":45,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The preferentially expressed antigen in melanoma (PRAME) is expressed in several hematologic malignancies, but either is not expressed or is expressed at only low levels in normal hematopoietic cells, making it a target for cancer therapy. PRAME is a tumor-associated antigen and has been described as a corepressor of retinoic acid signaling in solid tumor cells, but its function in hematopoietic cells is unknown. PRAME mRNA expression increased with chronic myeloid leukemia (CML) disease progression and its detection in late chronic-phase CML patients before tyrosine kinase inhibitor therapy was associated with poorer therapeutic responses and ABL tyrosine kinase domain point mutations. In leukemia cell lines, PRAME protein expression inhibited granulocytic differentiation only in cell lines that differentiate along this lineage after all-trans retinoic acid (ATRA) exposure. Forced PRAME expression in normal hematopoietic progenitors, however, inhibited myeloid differentiation both in the presence and absence of ATRA, and this phenotype was reversed when PRAME was silenced in primary CML progenitors. These observations suggest that PRAME inhibits myeloid differentiation in certain myeloid leukemias, and that its function in these cells is lineage and phenotype dependent. Lastly, these observations suggest that PRAME is a target for both prognostic and therapeutic applications.<\/jats:p>","DOI":"10.1182\/blood-2008-07-170282","type":"journal-article","created":{"date-parts":[[2009,7,22]],"date-time":"2009-07-22T22:23:35Z","timestamp":1248301415000},"page":"3299-3308","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":67,"title":["The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells"],"prefix":"10.1182","volume":"114","author":[{"given":"Vivian G.","family":"Oehler","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Guthrie","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Cummings","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Sabo","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Washington, Seattle;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent L.","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hematopathology, University of Washington, Seattle;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Gooley","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimei","family":"Yang","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam T.","family":"Epping","sequence":"additional","affiliation":[{"name":"Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Shou","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharmaceuticals Corporation, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Era","family":"Pogosova-Agadjanyan","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ladne","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek L.","family":"Stirewalt","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis L.","family":"Abkowitz","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Washington, Seattle;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111720512252900_B1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"issue":"8","key":"2019111720512252900_B2","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia.","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111720512252900_B3","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1046\/j.1365-2141.1998.00982.x","article-title":"PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells.","volume":"102","author":"van Baren","year":"1998","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111720512252900_B4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0165-4608(01)00570-2","article-title":"Clinical implications of PRAME gene expression in childhood acute myeloid leukemia.","volume":"133","author":"Steinbach","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"2019111720512252900_B5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"issue":"3","key":"2019111720512252900_B6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.leukres.2006.06.022","article-title":"PRAME mRNA levels in cases with chronic leukemia: clinical importance and review of the literature.","volume":"31","author":"Paydas","year":"2007","journal-title":"Leuk Res"},{"issue":"11","key":"2019111720512252900_B7","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.leukres.2007.02.016","article-title":"Epigenetic regulation of PRAME gene in chronic myeloid leukemia.","volume":"31","author":"Roman-Gomez","year":"2007","journal-title":"Leuk Res"},{"issue":"10","key":"2019111720512252900_B8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00277-008-0514-8","article-title":"Aberrant hypomethylation of the cancer-tesis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.","volume":"87","author":"Ortmann","year":"2008","journal-title":"Ann Hematol"},{"issue":"13","key":"2019111720512252900_B9","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1158\/1078-0432.CCR-03-0813","article-title":"The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.","volume":"10","author":"Oberthuer","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2019111720512252900_B10","doi-asserted-by":"crossref","first-page":"10639","DOI":"10.1158\/0008-5472.CAN-06-2522","article-title":"A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer.","volume":"66","author":"Epping","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"2019111720512252900_B11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.bjc.6604494","article-title":"PRAME expression and clinical outcome of breast cancer.","volume":"99","author":"Epping","year":"2008","journal-title":"Br J Cancer"},{"issue":"6","key":"2019111720512252900_B12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2141.2004.04982.x","article-title":"Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.","volume":"125","author":"McElwaine","year":"2004","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111720512252900_B13","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.3324\/haematol.13214","article-title":"The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.","volume":"93","author":"Santamaria","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"2019111720512252900_B14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2008-11-187724","article-title":"Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia (CN-AML).","volume":"114","author":"Santamar\u00eda","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111720512252900_B15","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.exphem.2005.06.007","article-title":"Regulation of hematopoiesis by retinoid signaling.","volume":"33","author":"Evans","year":"2005","journal-title":"Exp Hematol"},{"issue":"10","key":"2019111720512252900_B16","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/sj.leu.2402718","article-title":"The role of retinoids and retinoic acid receptors in normal hematopoiesis.","volume":"16","author":"Collins","year":"2002","journal-title":"Leukemia"},{"issue":"9","key":"2019111720512252900_B17","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0301-472X(99)00085-5","article-title":"Neutrophil maturation and the role of retinoic acid.","volume":"27","author":"Lawson","year":"1999","journal-title":"Exp Hematol"},{"issue":"2","key":"2019111720512252900_B18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2141.1995.tb05147.x","article-title":"All-trans retinoic acid shows multiple effects on survival, proliferation, and differentiation of human fetal CD34+ haematopoietic progenitor cells.","volume":"90","author":"Zauli","year":"1995","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111720512252900_B19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2008.176","article-title":"Decreased IRF8 expression found in aging hematopoietic progenitor\/stem cells.","volume":"23","author":"Stirewalt","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2019111720512252900_B20","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1634\/stemcells.2005-0484","article-title":"Anatomical compartments modify the response of human hematopoietic cells to a mitogenic signal.","volume":"24","author":"Nagasawa","year":"2006","journal-title":"Stem Cells"},{"issue":"4","key":"2019111720512252900_B21","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1073\/pnas.93.4.1470","article-title":"Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium.","volume":"93","author":"Petzer","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2019111720512252900_B22","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0301-472X(00)00515-4","article-title":"Multi-lineage expansion potential of primitive hematopoietic progenitors: superiority of umbilical cord blood compared to mobilized peripheral blood.","volume":"28","author":"Lewis","year":"2000","journal-title":"Exp Hematol"},{"issue":"11","key":"2019111720512252900_B23","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1182\/blood.V87.11.4831.bloodjournal87114831","article-title":"The pathophysiology of pure red cell aplasia: implications for therapy.","volume":"87","author":"Charles","year":"1996","journal-title":"Blood"},{"issue":"4","key":"2019111720512252900_B24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/86730","article-title":"Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer.","volume":"19","author":"Hughes","year":"2001","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2019111720512252900_B25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ygeno.2003.08.008","article-title":"Single-stranded linear amplification protocol results in reproducible and reliable microarray data from nanogram amounts of starting RNA.","volume":"83","author":"Stirewalt","year":"2004","journal-title":"Genomics"},{"key":"2019111720512252900_B26","unstructured":"Fred Hutchinson Cancer Research Center\n          Hutchinson Center Labs\n          Accessed August 1, 2009\n          \n            http:\/\/www.fhcrc.org\/science\/labs\/radich"},{"key":"2019111720512252900_B27","unstructured":"National Center for Biotechnology Information\n          Gene Expression Omnibus (GEO)\n          Accessed July 15, 2009\n          \n            http:\/\/www.ncbi.nlm.nih.gov\/geo"},{"key":"2019111720512252900_B28","unstructured":"National Institute of Allergy and Infectious Diseases\n          Database for Annotationm Visualization and Integrated Discovery (DAVID)\n          Accessed June 1, 2008\n          \n            http:\/\/david.abcc.ncifcrf.gov"},{"key":"2019111720512252900_B29","unstructured":"Open Biomedical Ontologies\n          The Gene Ontology\n          Accessed June 1, 2008\n          \n            http:\/\/www.geneontology.org\/"},{"issue":"5","key":"2019111720512252900_B30","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1186\/gb-2003-4-5-p3","article-title":"DAVID: Database for annotation, visualization, and integrated discovery.","volume":"4","author":"Dennis","year":"2003","journal-title":"Genome Biol"},{"issue":"2","key":"2019111720512252900_B31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/blood.V77.2.340.340","article-title":"Retinoic acid receptors in myeloid leukemia: characterization of receptors in retinoic acid-resistant K-562 cells.","volume":"77","author":"Robertson","year":"1991","journal-title":"Blood"},{"issue":"16","key":"2019111720512252900_B32","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1158\/0008-5472.CAN-04-4011","article-title":"Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo.","volume":"65","author":"Tajeddine","year":"2005","journal-title":"Cancer Res"},{"issue":"6","key":"2019111720512252900_B33","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/10428190802035933","article-title":"Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo.","volume":"49","author":"Tajeddine","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111720512252900_B34","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1128\/MCB.18.7.4301","article-title":"CCAAT\/enhancer binding protein alpha is a regulatory switch for induction of granulocytic development from bipotential myeloid progenitors.","volume":"18","author":"Radomska","year":"1998","journal-title":"Mol Cell Biol"},{"issue":"16","key":"2019111720512252900_B35","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1128\/MCB.02422-06","article-title":"PML-retinoic acid receptor alpha inhibits PML IV enhancement of PU. 1-induced C\/EBPepsilon expression in myeloid differentiation.","volume":"27","author":"Yoshida","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"3","key":"2019111720512252900_B36","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1182\/blood-2002-04-1207","article-title":"The gene encoding the transcriptional regulator Yin Yang (YY1) is a myeloid transforming gene interfering with neutrophilic differentiation.","volume":"101","author":"Erkeland","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2019111720512252900_B37","first-page":"954","article-title":"Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid.","volume":"119","author":"Passeron","year":"2009","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111720512252900_B38","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"issue":"9","key":"2019111720512252900_B39","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2008.161","article-title":"Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.","volume":"22","author":"Yong","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"2019111720512252900_B40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast crisis CML.","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"issue":"45","key":"2019111720512252900_B41","doi-asserted-by":"crossref","first-page":"17777","DOI":"10.1073\/pnas.0702518104","article-title":"A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors.","volume":"104","author":"Epping","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2019111720512252900_B42","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1158\/1535-7163.MCT-06-0418","article-title":"Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.","volume":"5","author":"Fiskus","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2019111720512252900_B43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1084\/jem.193.1.73","article-title":"Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.","volume":"193","author":"Kessler","year":"2001","journal-title":"J Exp Med"},{"issue":"5","key":"2019111720512252900_B44","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2008-04-150045","article-title":"Cytotoxic T lymphocytes directed to the Preferentially Expressed Antigen of Melanoma (PRAME) target chronic myeloid leukemia.","volume":"112","author":"Quintarelli","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111720512252900_B45","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood-2008-03-144071","article-title":"Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.","volume":"113","author":"Rezvani","year":"2009","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/114\/15\/3299\/1317412\/zh804109003299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/114\/15\/3299\/1317412\/zh804109003299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T20:51:44Z","timestamp":1574023904000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/114\/15\/3299\/125016\/The-preferentially-expressed-antigen-in-melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,8]]},"references-count":45,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2009,10,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-07-170282","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,8]]}}}